It has been found that hospitalized COVID-19 patients have a greater risk of dying if they are men or are obese or have complications from diabetes or hypertension (University of Maryland School of Medicine, 2020).
Yet, use of the diabetes drug metformin — before a diagnosis of COVID-19 — is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes (Crouse, et al. 2021).
[N]either BMI nor HbA1C were lower in metformin users who survived as compared to those who died (Table 4). While surprising, this is consistent with the notion that long-term glycemic control does not affect COVID-19 outcome.
While I understand at the moment that more investigation is needed to determine how Metformin helps, if BMI or HbA1C is not a contributing factor in the protective nature of Metformin, what other effects of Metformin on the body could be helping type 2 diabetics and how?
Crouse, A. B.; Grimes, T.; Li, P.; Might, M. Ovalle, F.; Shalev. A. (2021). Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Frontiers in Endocrinology 11(600439) https://doi.org/10.3389/fendo.2020.600439
University of Maryland School of Medicine. (2020). New study identifies greatest risk factors of mortality from COVID-19: Findings could help guide healthcare clinicians with managing hospitalized patients in the weeks ahead. ScienceDaily https://www.sciencedaily.com/releases/2020/12/201218152733.htm